脂肪性肝炎
疾病
癌症
脂肪肝
人口
生物信息学
医学
内科学
免疫学
肿瘤科
癌症研究
生物
环境卫生
作者
Xiaobo Wang,Liang Zhang,Bingning Dong
标识
DOI:10.1097/hep.0000000000000786
摘要
Liver cancer is the third leading cause of cancer-related deaths and ranks as the sixth most prevalent cancer type globally. NAFLD or metabolic dysfunction–associated steatotic liver disease, and its more severe manifestation, NASH or metabolic dysfunction–associated steatohepatitis (MASH), pose a significant global health concern, affecting approximately 20%–25% of the population. The increased prevalence of metabolic dysfunction–associated steatotic liver disease and MASH is parallel to the increasing rates of obesity-associated metabolic diseases, including type 2 diabetes, insulin resistance, and fatty liver diseases. MASH can progress to MASH-related HCC (MASH-HCC) in about 2% of cases each year, influenced by various factors such as genetic mutations, carcinogen exposure, immune microenvironment, and microbiome. MASH-HCC exhibits distinct molecular and immune characteristics compared to other causes of HCC and affects both men and women equally. The management of early to intermediate-stage MASH-HCC typically involves surgery and locoregional therapies, while advanced HCC is treated with systemic therapies, including anti-angiogenic therapies and immune checkpoint inhibitors. In this comprehensive review, we consolidate previous research findings while also providing the most current insights into the intricate molecular processes underlying MASH-HCC development. We delve into MASH-HCC–associated genetic variations and somatic mutations, disease progression and research models, multiomics analysis, immunological and microenvironmental impacts, and discuss targeted/combined therapies to overcome immune evasion and the biomarkers to recognize treatment responders. By furthering our comprehension of the molecular mechanisms underlying MASH-HCC, our goal is to catalyze the advancement of more potent treatment strategies, ultimately leading to enhanced patient outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI